Case Report: Evolution of intratumoral spatial heterogeneity assessed by [68Ga]Ga-DOTA-NOC PET/CT during dinutuximab beta therapy in pediatric high-risk neuroblastoma - Scorecard - MDSpire

Case Study: Changes in Intratumoral Spatial Heterogeneity Monitored by [68Ga]Ga-DOTA-NOC PET/CT During Dinutuximab Beta Treatment in Pediatric Patients with High-Risk Neuroblastoma

  • By

  • Yueran Chen

  • Qinfeng Xu

  • Haoyan Zhang

  • Yongjun Fang

  • Guoqiang Shao

  • July 21, 2026

Share

Clinical Scorecard: Case Study: Changes in Intratumoral Spatial Heterogeneity Monitored by [68Ga]Ga-DOTA-NOC PET/CT During Dinutuximab Beta Treatment in Pediatric Patients with High-Risk Neuroblastoma

At a Glance

CategoryDetail
ConditionHigh-Risk Neuroblastoma
Key MechanismsSomatostatin receptor (SSTR) expression and intratumoral heterogeneity
Target PopulationPediatric patients with high-risk neuroblastoma
Care SettingOncology and pediatric care

Key Highlights

  • Neuroblastoma exhibits substantial biological heterogeneity.
  • Elevated SSTR accumulation post-immunotherapy may indicate viable tumor subclones.
  • Dinutuximab beta is integrated into treatment regimens for high-risk neuroblastoma.
  • SSTR PET/CT aids in localizing viable residual disease.
  • Multidisciplinary evaluation is necessary for interpreting elevated SSTR uptake.

Guideline-Based Recommendations

Diagnosis

  • Utilize [68Ga]Ga-DOTA-NOC PET/CT for evaluating SSTR expression.

Management

  • Incorporate dinutuximab beta in induction and consolidation therapy.

Monitoring & Follow-up

  • Conduct routine monitoring in accordance with established clinical guidelines.

Risks

  • Consider the potential for therapy-resistant subclones in response assessment.

Patient & Prescribing Data

4-year-old male with high-risk neuroblastoma (Stage M)

Received four cycles of induction chemotherapy with dinutuximab beta.

Clinical Best Practices

  • Employ SSTR PET imaging to guide surgical navigation.
  • Evaluate histopathological findings in conjunction with imaging results.

Related Resources & Content

Original Source(s)

Case Report: Evolution of intratumoral spatial heterogeneity assessed by [68Ga]Ga-DOTA-NOC PET/CT during dinutuximab beta therapy in pediatric high-risk neuroblastoma

  • by Yueran Chen, Qinfeng Xu, Haoyan Zhang, Yongjun Fang, Guoqiang Shao

  • July 21, 2026

Related Content

Efficacy and safety analysis of immune checkpoint inhibitors combined with chemotherapy in the treatment of advanced triple-negative breast cancer: an umbrella meta-analysis

Targeting the AHR–IDO1–kynurenine pathway in TREM2+ macrophages restores antitumor immunity in thyroid cancer

Editorial: Navigating the landscape of IDH-mutant gliomas: advances in diagnosis, therapeutic management, and long-term monitoring